Stereotaxis (STXS)
(Real Time Quote from BATS)
$1.74 USD
-0.05 (-2.79%)
Updated Jul 5, 2024 02:18 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STXS 1.74 -0.05(-2.79%)
Will STXS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for STXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STXS
Stereotaxis (STXS) Gets CE Recertification for Approved Products
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
STXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
Other News for STXS
Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
Stereotaxis announces first heart rhythm treatments at Penn Presbyterian
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
Stereotaxis receives CE mark recertification under EU’s MDR regulatory framework